1 se duodenal gastrinomas are often minute and
multicentric.
2 e common in unicentric (262/278; 94.2%) than
multicentric (
49/126; 38.9%) disease (chi(2) 146.8; P <
3 DM plus DBT than for DM in the diagnosis of
multicentric (
51% [41 of 80] vs 37% [30 of 80], P = .002
4 ore 10 months of age and developed immature,
multicentric aggressive T-cell leukemia/lymphomas.
5 bjects in brain regions showing PrP-positive
multicentric amyloid deposits.
6 scant foci of spongiform change, and diffuse
multicentric amyloid plaques, selectively immunoreactive
7 ARTICIPANTS: Retrospective, cross-sectional,
multicentric analysis of administrative data from 5 821
8 Retrospective
multicentric analysis of patients treated for SU.
9 le to converge toward their conclusions in a
multicentric and multiethnic setting.
10 A
multicentric and retrospective study of 31 patients (22
11 r levels of HHV-8 DNA in those patients with
multicentric and visceral involvement than in those pati
12 t differences were found in the frequency of
multicentric and/or multifocal disease (luminal A, 27.3%
13 reports from 441 patients were reviewed for
multicentric and/or multifocal disease, lymph node invol
14 ple (when multifocal, it was formerly called
multicentric BAC).
15 the pathologic/radiologic concept of diffuse/
multicentric BAC.
16 Fifty-nine patients with multifocal or
multicentric breast lesions proven by either fine-needle
17 Multicentric cancer detected only at MR imaging was inva
18 An unsuspected additional
multicentric cancer seen only at MR imaging is likely cl
19 kely to be invasive than MR imaging-detected
multicentric cancers (88% vs 76%, P = .023).
20 MR imaging-detected
multicentric cancers and index cancers differed in histo
21 n the index quadrant despite the presence of
multicentric cancers elsewhere in the breast.
22 5%) (95% CI: 15, 36) had MR imaging-detected
multicentric cancers larger than 1 cm.
23 35) patients had larger MR imaging-detected
multicentric cancers than the known index lesion, and 18
24 atients (95% CI: 2, 13), MR imaging-detected
multicentric cancers were potentially more biologically
25 a minority of additional MR imaging-detected
multicentric cancers.
26 Multicentric carcinoid tumors occurred in 15 patients (1
27 liver metastases between solitary (18%) and
multicentric carcinoids (20%).
28 Multicentric carpal-tarsal osteolysis; multicentric oste
29 ization of monocyte-derived macrophages from
multicentric carpotarsal osteolysis (Online Mendelian In
30 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman desease.
31 HIV-associated
multicentric Castleman disease (HIV MCD) is a rare lymph
32 Successful treatment of HIV-associated
multicentric Castleman disease (HIV+MCD) with rituximab-
33 HIV-associated
multicentric Castleman disease (HIV-MCD) is a rare lymph
34 HIV-associated
multicentric Castleman disease (HIV-MCD) presents with s
35 Idiopathic
multicentric Castleman disease (iMCD) is a hematologic i
36 Idiopathic
multicentric Castleman disease (iMCD) is a rare and poor
37 Idiopathic
multicentric Castleman disease (iMCD) is a rare hematolo
38 O syndrome, a clinical subtype of idiopathic
multicentric Castleman disease (iMCD), consists of a con
39 Kaposi sarcoma (KS) herpesvirus-associated
multicentric Castleman disease (KSHV-MCD) is a lymphopro
40 Kaposi sarcoma herpesvirus (KSHV)-associated
multicentric Castleman disease (KSHV-MCD) is characteriz
41 been rarely reported as a heralding sign of
multicentric Castleman disease (MCD) and other lymphopro
42 is the causative agent of two B cell tumors,
multicentric Castleman disease (MCD) and primary effusio
43 virus/human herpesvirus 8 is associated with
multicentric Castleman disease (MCD) and primary effusio
44 (KSHV) led to recognition of KSHV-associated
multicentric Castleman disease (MCD) as a distinct lymph
45 Kaposi sarcoma herpesvirus (KSHV)-associated
multicentric Castleman disease (MCD) is a lymphoprolifer
46 Kaposi sarcoma herpesvirus (KSHV)-associated
multicentric Castleman disease (MCD) is a lymphoprolifer
47 Multicentric Castleman disease (MCD) is a lymphoprolifer
48 Kaposi sarcoma herpesvirus (KSHV)-associated
multicentric Castleman disease (MCD) is a polyclonal B-c
49 HIV-associated
multicentric Castleman disease (MCD) is associated with
50 a (KS), primary effusion lymphoma (PEL), and
multicentric Castleman disease (MCD) patients.
51 e causative agent of Kaposi sarcoma (KS) and
multicentric Castleman disease (MCD), a life-threatening
52 with primary effusion lymphoma (PEL) and/or
multicentric Castleman disease (MCD), and in 18 (60.0%)
53 disorders: primary effusion lymphoma (PEL),
multicentric Castleman disease (MCD), and MCD-associated
54 igens were investigated in patients with KS,
multicentric Castleman disease (MCD), and primary effusi
55 ary effusion lymphoma (PEL), and a subset of
multicentric Castleman disease (MCD).
56 mary effusion lymphoma, and plasma cell-type
multicentric Castleman disease (MCD).
57 , namely primary effusion lymphoma (PEL) and
multicentric Castleman disease (MCD).
58 s and contribute to the pathogenesis of KSHV
multicentric Castleman disease (MCD).
59 nd 4 from Central/South America), and 2 with
multicentric Castleman disease (MCD).
60 a (KS), primary effusion lymphoma (PEL), and
multicentric Castleman disease (MCD).
61 d with monotypic (IgMlambda) plasmablasts in
multicentric Castleman disease (MCD).
62 quences have been described in some cases of
multicentric Castleman disease (MCD).
63 sting as primary effusion lymphoma (PEL) and
multicentric Castleman disease (MCD).
64 a (KS), primary effusion lymphoma (PEL), and
multicentric Castleman disease (MCD).
65 Multicentric Castleman disease and hemophagocytic syndro
66 Localized and
multicentric Castleman disease are different clinical di
67 1 patient was diagnosed with KSHV-associated
multicentric Castleman disease at autopsy.
68 (KS) to either primary effusion lymphoma or
multicentric Castleman disease B-cell malignancies, and
69 lasias such as primary effusion lymphoma and
multicentric Castleman disease in AIDS patients.
70 ia and persistent lymphadenopathy resembling
multicentric Castleman disease in rhesus macaques (RMs)
71 HIV-associated plasmablastic
multicentric Castleman disease is an increasingly freque
72 Finally, although
multicentric Castleman disease is not a neoplastic condi
73 ANA in a subset of cells in lytically active
multicentric Castleman disease lesions.
74 sus as a first-line treatment for idiopathic
multicentric Castleman disease on the basis of durable e
75 tment with rituximab in posttrans-plantation
multicentric Castleman disease patients and non-neoplast
76 d entities: Kaposi sarcoma, HHV-8-associated
multicentric Castleman disease with microlymphomas and a
77 n-years, 95%CI 0.26-1.52): 3 skin-only KS, 1
multicentric Castleman disease, 1 allograft KS.
78 ere KSHV disease (2 with visceral KS, 1 with
multicentric Castleman disease, and 1 with primary effus
79 deficiency virus (HIV)-infected men with KS,
multicentric Castleman disease, or primary effusion lymp
80 sarcoma (KS), primary effusion lymphoma, and
multicentric Castleman disease.
81 ma (KS), primary effusion lymphoma (PEL) and
multicentric Castleman disease.
82 expression of TbetaRII in Kaposi sarcoma and
multicentric Castleman disease.
83 a (KS), primary effusion lymphoma (PEL), and
multicentric Castleman disease.
84 ith KS, primary effusion lymphoma (PEL), and
multicentric Castleman disease.
85 initial presentation as having localized or
multicentric Castleman disease.
86 ong use required by patients with idiopathic
multicentric Castleman disease.
87 e parameters between PEL and KSHV-associated
multicentric Castleman disease.
88 c interleukin (IL)-6 related KSHV-associated
multicentric Castleman disease.
89 induced hyperplasia to monoclonal neoplasia:
multicentric Castleman's disease (CD), Kaposi's sarcoma
90 readily detected in KSHV-positive cells from
multicentric Castleman's disease (MCD) and Kaposi's sarc
91 Multicentric Castleman's disease (MCD) describes a heter
92 effusion lymphoma (PEL) cell lines, PEL and
multicentric Castleman's disease (MCD) tumors, Kaposi's
93 a (KS), primary effusion lymphoma (PEL), and
multicentric Castleman's disease (MCD), all of which are
94 us casually linked to Kaposi's sarcoma (KS),
multicentric Castleman's disease (MCD), and primary effu
95 alignancies including Kaposi's sarcoma (KS),
multicentric Castleman's disease (MCD), and primary effu
96 ic agent of primary effusion lymphoma (PEL),
multicentric Castleman's disease (MCD), and the inflamma
97 arcoma, primary effusion lymphoma (PEL), and
multicentric Castleman's disease (MCD), in addition to a
98 f HHV-8-associated Kaposi's sarcoma, PEL and
multicentric Castleman's disease (MCD), in addition to p
99 man's disease (UCD) or the dominant focus in
multicentric Castleman's disease (MCD), nature of the su
100 a (KS), primary effusion lymphoma (PEL), and
multicentric Castleman's disease (MCD), three diseases t
101 a (KS), primary effusion lymphoma (PEL), and
multicentric Castleman's disease (MCD).
102 a (KS), primary effusion lymphoma (PEL), and
multicentric Castleman's disease (MCD).
103 sorders, primary effusion lymphoma (PEL) and
multicentric Castleman's disease (MCD).
104 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease (MCD).
105 arcoma, primary effusion lymphoma (PEL), and
multicentric Castleman's disease (MCD).
106 ancies: primary effusion lymphomas (PEL) and
multicentric Castleman's disease (MCD).
107 ry effusion lymphomas (PEL), and a subset of
multicentric Castleman's disease (MCD).
108 cavity-based primary effusion lymphomas, and
multicentric Castleman's disease (MCD).
109 d B-cell lymphomas (BCBLs) and in lesions of
multicentric Castleman's disease (MCD).
110 resemble KSHV-associated diseases including
multicentric Castleman's disease and non-Hodgkin's lymph
111 d malignancies, the plasmablastic variant of
multicentric Castleman's disease and PEL.
112 to two B cell lymphoproliferative disorders,
multicentric Castleman's disease and primary effusion ly
113 ive care alone for patients with symptomatic
multicentric Castleman's disease and well tolerated with
114 Multicentric Castleman's disease describes a group of po
115 tified 626 (33%) patients with HHV8-negative
multicentric Castleman's disease from 1923 cases of mult
116 24 (19%) of 128 patients with idiopathic
multicentric Castleman's disease had a diagnosis of a se
117 Human herpesvirus 8 (HHV8) causes
multicentric Castleman's disease in immunosuppressed pat
118 First-line treatments for idiopathic
multicentric Castleman's disease included corticosteroid
119 Clinical features of idiopathic
multicentric Castleman's disease included multicentric l
120 Multicentric Castleman's disease is a rare lymphoprolife
121 The cause of HHV8-negative
multicentric Castleman's disease is idiopathic; such cas
122 128 patients with idiopathic
multicentric Castleman's disease met all inclusion crite
123 of centralised information about idiopathic
multicentric Castleman's disease represents a major chal
124 e cells infected with human herpesvirus-8 in
multicentric Castleman's disease support lytic replicati
125 arcoma, primary effusion lymphoma (PEL), and
multicentric Castleman's disease through autocrine or pa
126 K1 was readily detected in
multicentric Castleman's disease tissues, whereas it was
127 egated data for 127 patients with idiopathic
multicentric Castleman's disease were presented from cli
128 be the etiologic agent of Kaposi's sarcoma,
multicentric Castleman's disease, and AIDS-associated pr
129 KSHV causes primary effusion lymphomas,
multicentric Castleman's disease, and Kaposi's sarcoma.
130 (KSHV) is the etiologic agent for KS tumors,
multicentric Castleman's disease, and primary effusion l
131 us (KSHV) is found in Kaposi's sarcoma (KS),
multicentric Castleman's disease, and primary effusion l
132 with the development of Kaposi's sarcoma and
multicentric Castleman's disease, as well as a rare form
133 ssociated with primary effusion lymphoma and
multicentric Castleman's disease, as well as its namesak
134 iological agent of three human malignancies:
multicentric Castleman's disease, primary effusion lymph
135 tures, treatment, and outcomes of idiopathic
multicentric Castleman's disease, which accounts for at
136 idiopathic; such cases are called idiopathic
multicentric Castleman's disease.
137 a (KS), primary effusion lymphoma (PEL), and
multicentric Castleman's disease.
138 arcoma, primary effusion lymphoma (PEL), and
multicentric Castleman's disease.
139 interleukin 6-in HIV-negative patients with
multicentric Castleman's disease.
140 rus-8-seronegative patients with symptomatic
multicentric Castleman's disease.
141 arcoma, primary effusion lymphoma (PEL), and
multicentric Castleman's disease.
142 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease.
143 ses, including primary effusion lymphoma and
multicentric Castleman's disease.
144 include primary effusion lymphoma (PEL) and
multicentric Castleman's disease.
145 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease.
146 arcoma, primary effusion lymphoma (PEL), and
multicentric Castleman's disease.
147 athogenesis of primary effusion lymphoma and
multicentric Castleman's disease.
148 ies, including primary effusion lymphoma and
multicentric Castleman's disease.
149 i's sarcoma, primary effusion lymphomas, and
multicentric Castleman's disease.
150 sarcoma (KS), primary effusion lymphoma, and
multicentric Castleman's disease.
151 primary effusion lymphoma, and some forms of
multicentric Castleman's disease.
152 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease.
153 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease.
154 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease.
155 a (KS), primary effusion lymphoma (PEL), and
multicentric Castleman's disease.
156 primary effusion lymphoma, and plasmablastic
multicentric Castleman's disease.
157 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease.
158 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease.
159 as well as of primary effusion lymphoma and
multicentric Castleman's disease.
160 gnancies, KS, primary effusion lymphoma, and
multicentric Castleman's disease.
161 usion lymphoma and the plasmablastic form of
multicentric Castleman's disease.
162 imary effusion lymphoma and in some cases of
multicentric Castleman's disease.
163 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease.
164 as well as in primary effusion lymphoma and
multicentric Castleman's disease.
165 tve disorders, primary effusion lymphoma and
multicentric Castleman's disease.
166 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease.
167 of KS, primary effusion lymphoma (PEL), and
multicentric Castleman's disease.
168 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease.
169 nked with KS, primary effusion lymphoma, and
multicentric Castleman's disease.
170 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease.
171 sarcoma (KS), primary effusion lymphoma, and
multicentric Castleman's disease.
172 primary effusion lymphoma and some cases of
multicentric Castleman's disease.
173 related non-Hodgkin's lymphomas (NHL) and in
multicentric Castleman's disease.
174 in body cavity-based lymphomas (BCBL) and in
multicentric Castleman's disease.
175 ody cavity-based lymphomas, and AIDS-related
multicentric Castleman's disease.
176 ted lymphomas, and from a high proportion of
multicentric Castleman's disease.
177 phoma (PEL) and the plasmablastic variant of
multicentric Castleman's disease.
178 cluding AIDS-associated Kaposi's sarcoma and
multicentric Castleman's disease.
179 ch accounts for at least 33% of all cases of
multicentric Castleman's disease.
180 ntric Castleman's disease from 1923 cases of
multicentric Castleman's disease.
181 posi sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease.
182 , treatments for, and outcomes of idiopathic
multicentric Castleman's disease.
183 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease; in all of these diseas
184 s been associated with both malignancies and
multicentric Castleman's disease; the latter is a rare a
185 features, is divided into unicentric CD and
multicentric CD (MCD) according to the clinical presenta
186 CD includes unicentric CD (UCD) and
multicentric CD (MCD), the latter of which is divided in
187 Multicentric chromosomes are often found in tumor cells
188 ut not inactive, centromeres of prometaphase
multicentric chromosomes using antibodies to the cytopla
189 romotes formation of ectopic centromeres and
multicentric chromosomes, which causes chromosome misseg
190 Brachytherapy should be included in
multicentric clinical trials in young children.
191 of canine hematological malignancy where the
multicentric (
cMCL) form accounts for 75% of all cases.
192 tory cohort was independently validated in a
multicentric cohort of 194 AML patients.
193 We performed a retrospective
multicentric cohort study by using molecular and clinica
194 SIGN, SETTING, AND PARTICIPANTS: Prospective
multicentric cohort study conducted at 3 referral center
195 A
multicentric cross-sectional study was conducted among M
196 rtical evoked potentials recorded in a large
multicentric database.
197 more likely to help detect multifocal and/or
multicentric disease and lymph node involvement in lumin
198 ry, but complete remissions in patients with
multicentric disease have been achieved only with chemot
199 The 8 patients with
multicentric disease were further subdivided according t
200 In
multicentric disease, outcomes are comparable between de
201 ndependently predictive of multifocal and/or
multicentric disease.
202 1.2% vs 34.4%; chi(2) 28.6; P < 0.0001) than
multicentric disease.
203 combination chemotherapy, or prednisone for
multicentric disease.
204 ntly compared with R-CHOP(21) induction in a
multicentric European protocol.
205 CDC pathogenesis, we undertook a prospective
multicentric exploratory study in 44 CDC patients at dia
206 of the first recognized autosomal-recessive,
multicentric forms of the disorder.
207 By screening a
multicentric French cohort of 448 unrelated probands pre
208 causative agent of Kaposi's sarcoma (KS), a
multicentric growth factor-dependent tumor common in AID
209 r methods have been proposed to discriminate
multicentric hepatocellular carcinomas (HCC) from intrah
210 ining age, gender, centricity (unicentric vs
multicentric),
histopathologic type (hyaline vascular [H
211 However, comorbidity was frequent, including
multicentric infection or infectious disease in combinat
212 The study was conducted in a
multicentric institutional practice setup and included 2
213 -related disorders were identified through a
multicentric international collaboration made possible b
214 We then undertook a
multicentric international phase III study to compare th
215 A
multicentric,
international ATTRwt-CM patient cohort wit
216 Overall, the size of MR imaging-detected
multicentric invasive cancers (median, 0.6 cm; range, 0.
217 Six patients had
multicentric involvement (4-15 lesions), primarily of th
218 heavy smokers consecutively recruited by the
Multicentric Italian Lung Detection, or MILD, trial.
219 e hypothesis that the spindle cells in these
multicentric lesions originate from a single clone of pr
220 ffer between the index lesion and additional
multicentric lesions seen only at MR imaging.
221 in breast cancer patients with multifocal or
multicentric lesions, contrary to the common belief of s
222 , selection for an X-linked allele in clonal
multicentric lesions.
223 14%) exhibited multifocal lesions; 20 (12%),
multicentric lesions; 39 (23%), additional ipsilateral l
224 ic multicentric Castleman's disease included
multicentric lymphadenopathy (128/128), anaemia (79/91),
225 V-945 LTR and SU into FeLV-A/61E resulted in
multicentric lymphoma of non-T-cell origin.
226 a T-cell origin to an as yet uncharacterized
multicentric lymphoma that did not contain T cells.
227 edict the outcome of chemotherapy for canine
multicentric lymphomas.
228 us macaque (Macaca mulatta) that developed a
multicentric lymphoproliferative disorder (LPD).
229 It is almost always
multicentric (
MCD) and linked to human herpesvirus 8 (HH
230 whether patients with clinical multifocal or
multicentric (
MFMC) breast cancer determined by mammogra
231 across sites, which is especially useful for
multicentric molecular radiotherapy studies.
232 In contrast,
multicentric monophasic IMDS patients with putative evid
233 This retrospective
multicentric,
national study included 98 children and 26
234 A cross-sectional,
multicentric,
nationwide survey was conducted between Se
235 e progression of Parkinson's disease and its
multicentric neurodegeneration provides the best hope of
236 A
multicentric,
noninferiority, randomized controlled tria
237 In this
multicentric observational retrospective cohort study, w
238 We designed a
multicentric,
observational study to test if Procalciton
239 mixed) and two clinical types (localized and
multicentric)
of Castleman disease have been described.
240 and modular data handling platform to enable
multicentric off-site image reading for incidental findi
241 Multicentric or multifocal breast cancer is considered a
242 ive predictive values of SLN localization in
multicentric or multifocal breast lesions.
243 atients mammographically suspected of having
multicentric or multifocal disease.
244 I study in which patients with symptomatic,
multicentric or unresectable, unicentric CD received sil
245 We discover a
multicentric organization with fields that vary dramatic
246 The
multicentric osteolyses are notable for interphalangeal
247 mal recessive osteolysis/arthritis syndrome,
multicentric osteolysis with arthritis (MOA) (MIM #60515
248 tly described an autosomal recessive form of
multicentric osteolysis with carpal and tarsal resorptio
249 Multicentric carpal-tarsal osteolysis;
multicentric osteolysis, nodulosis, and arthropathy; and
250 In this open-label, randomized,
multicentric,
parallel group clinical trial, 240 patient
251 ers, leaving a gap to the reality of diverse
multicentric patient data.
252 rials 1 single method easily applicable in a
multicentric PET review must be selected and kept all al
253 In a prospective and
multicentric phase III clinical study, the value of (18)
254 77 developed hyperplastic LPD resembling the
multicentric plasma cell variant of Castleman's disease,
255 meters of renal function and morphology in a
multicentric population-based cohort.
256 We find that each
multicentric primary tumor harbors distinct oncogenic al
257 The VALIDate study is an ongoing
multicentric prospective cohort study launched in April
258 sk factors have been identified to date, but
multicentric prospective studies on anastomotic leak aft
259 We performed a
multicentric prospective trial including all ABO-incompa
260 This
multicentric,
prospective, observational, real-life stud
261 Method: We conducted a
multicentric,
quasiexperimental, interrupted time series
262 nagement of stress urinary incontinence with
multicentric randomized controlled trials.
263 However, further
multicentric randomized studies will confirm the exact r
264 NCAY (MONotherapy of TiviCAY) was a 48-week,
multicentric,
randomized, open-label, 12% noninferiority
265 A retrospective
multicentric record analysis.
266 (retrospective
multicentric registry and Mainz Intracoronary Database.
267 In this cohort study, a
multicentric registry of patients with BCP (from Cancer
268 ry, radiographic, and histologic findings in
multicentric reticulohistiocytosis are reviewed.
269 We describe a patient with
multicentric reticulohistiocytosis in whom complete remi
270 s of complete or near-complete remissions of
multicentric reticulohistiocytosis reported in the Engli
271 In addition, all published cases of
multicentric reticulohistiocytosis which included report
272 report describes the case of a patient with
multicentric reticulohistiocytosis.
273 Design, Setting, and Participants:
Multicentric retrospective cohort study of images from 1
274 Multicentric retrospective observational study including
275 We conducted a
multicentric retrospective study by collecting cases fro
276 The primary endpoint of this
multicentric retrospective study was ICU survival of pat
277 A
multicentric,
retrospective collection of real-world dat
278 A retrospective
multicentric study (9 French kidney transplant units of
279 A retrospective
multicentric study (9 French kidney transplant units of
280 This retrospective
multicentric study included 213 patients who underwent L
281 This retrospective
multicentric study included 53 patients with a history o
282 We conducted a
multicentric study on nonimmunized patients >=65 years o
283 In conclusion, this large
multicentric study suggests that higher child adiposity
284 This
multicentric study was conducted between 2009 and 2014 i
285 An observational, prospective,
multicentric study was conducted in patients with confir
286 Purpose: The aim of this retrospective
multicentric study was to develop and evaluate a prognos
287 The aim of this retrospective
multicentric study was to develop and evaluate a prognos
288 A
multicentric study with a large number of patients is ne
289 Methods: In this retrospective
multicentric study, patients with LACC and PALN involvem
290 In a prospective,
multicentric study, serum samples of 616 patients with t
291 This large
multicentric survey shows that surgery is in current pra
292 We developed a
multicentric Swiss protocol for ABO-incompatible kidney
293 122 patients with PTCL was collected from a
multicentric T-cell lymphoma consortium (TENOMIC).
294 Purpose Kaposi's sarcoma (KS) is a
multicentric tumor caused by Kaposi's sarcoma-associated
295 y offer SLNB in patients who have cT3-T4c or
multicentric tumors (clinically node-negative) or ductal
296 aindications to breast preservation included
multicentric tumors, diffuse indeterminate microcalcific
297 Women with operable breast cancer and
multicentric tumors, with ductal carcinoma in situ (DCIS
298 Women with operable breast cancer and
multicentric tumors, with ductal carcinoma in situ, who
299 This prospective,
multicentric,
uncontrolled pilot study enrolled patients
300 chronic therapy-refractory HE in a European
multicentric working group and to identify patients who